Clinical Trials Logo
  1. Home
  2. Hodgkin Disease
  3. NCT01874054

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

Hodgkin Disease Clinical Trial

Official title:
A Phase 1/2 Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)

Clinical Trial Summary

The purpose of this study is to assess safety and efficacy of brentuximab vedotin in combination with bendamustine in patients with relapsed or refractory Hodgkin lymphoma. It is an open-label, 2-stage study designed to determine the recommended dose level of bendamustine in combination with brentuximab vedotin. The study will assess the safety profile of the combination treatment and determine what proportion of patients achieve a complete remission.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01874054
Study type Interventional
Source Seattle Genetics, Inc.
Contact
Status Completed
Phase Phase 1/Phase 2
Start date June 2013
Completion date February 20, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT02057185 - Occupational Status and Hematological Disease
Active, not recruiting NCT02979522 - A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma Phase 1/Phase 2
Completed NCT00540007 - Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma Phase 2
Active, not recruiting NCT03755414 - Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation Phase 1
Recruiting NCT01676805 - Tissue Collection for Studies of Lymph Cancer
Completed NCT02378337 - Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality N/A
Terminated NCT00916045 - Pilot Study of Unrelated Cord Blood Transplantation Phase 2
Completed NCT00534989 - Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT N/A
Terminated NCT00393380 - Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Phase 2
Completed NCT00062868 - LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma Phase 1
Completed NCT00388349 - Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease Phase 2
Recruiting NCT05255601 - A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma Phase 1/Phase 2
Completed NCT01716806 - A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Phase 2
Active, not recruiting NCT04998331 - A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin
Completed NCT02389101 - Molecular and Whole-body MR Imaging in Lymphomas N/A
Completed NCT00871702 - Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease Phase 1
Recruiting NCT02589548 - Brazilian Prospective Hodgkin Lymphoma Registry
Completed NCT00398411 - Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells Phase 3
Terminated NCT00514722 - Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies N/A
Terminated NCT00225173 - Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease Phase 2